Buckley M M, Lamb H M
Adis International Limited, Auckland, New Zealand.
Drugs Aging. 1997 Jul;11(1):61-86. doi: 10.2165/00002512-199711010-00006.
Idarubicin is an anthracycline agent available as both oral and intravenous formulations. The oral formulation has demonstrated efficacy in the treatment of advanced breast cancer, low-grade non-Hodgkin's lymphoma, myelodysplastic syndromes and as first-line induction therapy of acute myelogenous leukaemia where intravenous anthracycline treatment is precluded. It also has potential in ameliorating blast crisis of chronic myelogenous leukaemia and in multiple myeloma. The most frequent adverse effects associated with oral idarubicin are those commonly found with anthracyclines, namely myelosuppression, nausea and vomiting, diarrhoea and mucositis. There appears to be minimal significant cardiotoxicity with oral idarubicia. In summary; available data concerning oral idarubicin in haematological malignancies and advanced breast cancer are sufficiently encouraging to warrant further research. To maximise the use of oral idarubicin, future studies should define the optimal dose for elderly patients, its comparative efficacy with other available regimens and address quality-of-life and pharmacoeconomic issues associated with the substitution of oral for intravenous chemotherapy.
伊达比星是一种蒽环类药物，有口服和静脉注射两种剂型。口服制剂已证明对晚期乳腺癌、低度非霍奇金淋巴瘤、骨髓增生异常综合征有效，并且在不能进行静脉注射蒽环类药物治疗的情况下，可作为急性髓性白血病的一线诱导疗法。它在改善慢性髓性白血病的急变期以及多发性骨髓瘤方面也有潜力。与口服伊达比星相关的最常见不良反应是蒽环类药物常见的不良反应，即骨髓抑制、恶心和呕吐、腹泻以及粘膜炎。口服伊达比星似乎几乎没有明显的心脏毒性。总之，关于口服伊达比星在血液系统恶性肿瘤和晚期乳腺癌中的现有数据足以令人鼓舞，值得进一步研究。为了最大限度地使用口服伊达比星，未来的研究应确定老年患者的最佳剂量、其与其他现有治疗方案的相对疗效，并解决与口服化疗替代静脉化疗相关的生活质量和药物经济学问题。
